<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34473245</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset.</ArticleTitle><Pagination><StartPage>e482</StartPage><EndPage>e490</EndPage><MedlinePgn>e482-e490</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciab759</ELocationID><Abstract><AbstractText Label="BACKGROUND">Few robust longitudinal data on long-term coronavirus disease 2019 (COVID-19) symptoms are available. We evaluated symptom onset, severity and recovery across the full spectrum of disease severity, up to one year after illness onset.</AbstractText><AbstractText Label="METHODS">The RECoVERED Study is a prospective cohort study based in Amsterdam, the Netherlands. Participants aged&#x2005;&#x2265;18 years were enrolled following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis via the local public health service and from hospitals. Standardized symptom questionnaires were completed at enrollment, 1 week and month later, and monthly thereafter. Clinical severity was defined according to World Health Organization (WHO) criteria. Kaplan-Meier methods were used to compare time from illness onset to symptom recovery, by clinical severity. We examined determinants of time to recovery using multivariable Cox proportional hazards models.</AbstractText><AbstractText Label="RESULTS">Between 11 May 2020 and 1 May 2021, 342 COVID-19 patients (192 [56%] male) were enrolled, of whom 99/342 (29%) had mild, 145/342 (42%) moderate, 56/342 (16%) severe, and 42/342 (12%) critical disease. The proportion of participants who reported at least 1 persistent symptom at 12 weeks after illness onset was greater in those with severe/critical disease (86.7% [95% confidence interval {CI}&#x2005;=&#x2005;76.5-92.7%]) compared to those with mild or moderate disease (30.7% [95% CI&#x2005;=&#x2005;21.1-40.9%] and 63.8% [95% CI&#x2005;=&#x2005;54.8-71.5%], respectively). At 12 months after illness onset, two-fifths of participants (40.7% [95% CI&#x2005;=&#x2005;34.2-7.1]) continued to report&#x2005;&#x2265;1 symptom. Recovery was slower in female compared to male participants (adjusted hazard ratio [aHR] 0.65 [95% CI&#x2005;=&#x2005;.47-.92]) and those with a body mass index [BMI] &#x2005;&#x2265;30kg/m2 compared to BMI&#x2005;&lt;25kg/m2 (hazard ratio [HR] 0.62 [95% CI&#x2005;=&#x2005;.39-.97]).</AbstractText><AbstractText Label="CONCLUSIONS">COVID-19 symptoms persisted for one year after illness onset, even in some individuals with mild disease. Female sex and obesity were the most important determinants of speed of recovery from symptoms.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wynberg</LastName><ForeName>Elke</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8245-086X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Willigen</LastName><ForeName>Hugo D G</ForeName><Initials>HDG</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dijkstra</LastName><ForeName>Maartje</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2561-7659</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stichting Human Immunodeficiency Virus (HIV) Monitoring, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kootstra</LastName><ForeName>Neeltje A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Aardweg</LastName><ForeName>Joost G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gils</LastName><ForeName>Marit J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matser</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Marije R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenstra</LastName><ForeName>Tjalling</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bree</LastName><ForeName>Godelieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jong</LastName><ForeName>Menno D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RECoVERED Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">recovery</Keyword><Keyword MajorTopicYN="N">symptoms</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Agard</LastName><ForeName>Ivette</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayal</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cavdar</LastName><ForeName>Floor</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craanen</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davidovich</LastName><ForeName>Udi</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deuring</LastName><ForeName>Annemarieke</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Annelies</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ersan</LastName><ForeName>Ertan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Grande</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koedoot</LastName><ForeName>Nelleke</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebbink</LastName><ForeName>Romy</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loomans</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makowska</LastName><ForeName>Agata</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>du Maine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Man</LastName><ForeName>Ilja</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Meij</LastName><ForeName>Lizenka</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Polanen</LastName><ForeName>Marleen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oud</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reid</LastName><ForeName>Clark</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Storey</LastName><ForeName>Leeann</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Wijk</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34473245</ArticleId><ArticleId IdType="pmc">PMC8522402</ArticleId><ArticleId IdType="doi">10.1093/cid/ciab759</ArticleId><ArticleId IdType="pii">6362727</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W-j, Ni Z-y, Hu Y, et al. . Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Wu D, Chen H, et al. . Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. (1756&#x2013;1833 [Electronic]).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin L, Savale L, Pham T, et al. . Four-month clinical status of a cohort of patients after hospitalization for COVID-19. (1538-3598 [Electronic]).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7970386</ArticleId><ArticleId IdType="pubmed">33729425</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Guida F, Polesel J, et al. . Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allerg Rhinol 2021: 1&#x2013;4. Available at: 10.1002/alr.22832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22832</ArticleId><ArticleId IdType="pmc">PMC9291310</ArticleId><ArticleId IdType="pubmed">34109765</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4:e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>
BodyPolitic. 
About us.
https://www.wearebodypolitic.com/about-body-politic. Accessed 7 June 2021.</Citation></Reference><Reference><Citation>Calvo-Bonacho E, Catalina-Romero C, Fern&#xe1;ndez-Labandera C, et al. . COVID-19 and sick leave: an analysis of the Ibermutua cohort of over 1,651,305 Spanish workers in the first trimester of 2020. (2296&#x2013;2565 [Print]).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604328</ArticleId><ArticleId IdType="pubmed">33194983</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SI, Pierri N, Presbitero AF. Tracking the economic impact of COVID-19 and mitigation policies in Europe and the United States. IMF Working Papers 2020; (Working Paper No. 20/125).</Citation></Reference><Reference><Citation>RIVM. Status validatie SARS-CoV-2 antigeensneltesten. In: Infectieziektebestrijding C. 19 July 2021 ed. Bilthoven: RIVM, 2021.</Citation></Reference><Reference><Citation>GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. . An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun 2020; 11:3436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338506</ArticleId><ArticleId IdType="pubmed">32632160</ArticleId></ArticleIdList></Reference><Reference><Citation>
ISARIC. 
Clinical data collection &#x2013; the COVID-19 case report forms (CRFs).
https://isaric.org/research/covid-19-clinical-research-resources/covid-19-crf/. Accessed 18 April 2020.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19 NG188. Vol. 2021. London: NICE, 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Clinical management of COVID-19. WHO Headquarters (HQ). World Health Organization, 2021.</Citation></Reference><Reference><Citation>
Council. MR. 
MRC Dyspnoea scale/MRC Breathlessness scale.
https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/. Accessed 18 April 2020.</Citation></Reference><Reference><Citation>Stronks K, Kulu-Glasgow I, Agyemang C. The utility of &#x2018;country of birth&#x2019; for the classification of ethnic groups in health research: the Dutch experience. Ethn Health 2009; 14:255&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">19052941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L, Drake TM, Pauley E, et al. . Long Covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. medRxiv 2021. Doi: 10.1101/2021.03.18.21253888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.18.21253888</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ayoubkhani DG. Update on long COVID prevalence estimate.https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021. Accessed 8 April 2021.</Citation></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, et al. . Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA 2021; 325:2015&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027932</ArticleId><ArticleId IdType="pubmed">33825846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. Long COVID: let patients help define long-lasting COVID symptoms. Nature 2020; 586: 170.</Citation><ArticleIdList><ArticleId IdType="pubmed">33029005</ArticleId></ArticleIdList></Reference><Reference><Citation>
RIVM. 
Long COVID.
https://www.rivm.nl/en/novel-coronavirus-covid-19/long-covid. Accessed 6 April.</Citation></Reference><Reference><Citation>McLaren L. Socioeconomic status and obesity. Epidemiol Rev 2007; 29: 29&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets LGA, Belay B, Freedman D, et al. . Body mass index and risk for COVID-19&#x2013;related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death&#x2014;United States, March&#x2013;December 2020. 2021.</Citation></Reference><Reference><Citation>Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. The hidden cost of chronic fatigue to patients and their families. BMC Health Serv Res 2010; 10:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845126</ArticleId><ArticleId IdType="pubmed">20202216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung 2021; 199:113&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyer L, Wynberg E, Buster M, et al. . Hospitalisation rates differed by city district and ethnicity during the first wave of COVID-19 in Amsterdam, the Netherlands. medRxiv 2021. doi: 10.1101/2021.03.15.21253597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.15.21253597</ArticleId><ArticleId IdType="pmc">PMC8456400</ArticleId><ArticleId IdType="pubmed">34551752</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyer L, Boyd A, Schinkel J, et al. . SARS-CoV-2 antibody prevalence and determinants of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June&#x2013;October 2020. medRxiv 2021. doi: 10.1101/2021.03.08.21252788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.08.21252788</ArticleId><ArticleId IdType="pmc">PMC8739540</ArticleId><ArticleId IdType="pubmed">34992110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewell BL. Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages. Lancet Public Health 2021; 6:e267&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8041364</ArticleId><ArticleId IdType="pubmed">33857454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>